New York, August 24, 2022 /PRNewswire/ — GLO Pharma, Inc., parent company of the breakthrough subtopical skincare brand Ourself, today announces the appointment. Brent Saunders to its Board of Directors. Mr. Saunders, who currently serves as Executive Chairman of The Beauty Health Company, will join the Board effective immediately. His appointment adds a new seat to the GLO Pharma board, which now has six members and is headed by a chairman. Scott L. Glenn.
Mr. Saunders is a respected innovator who brings to the board his extensive leadership experience in the biopharma and medical aesthetics sectors, having led numerous mergers and acquisitions and served in multiple leadership roles at major global pharmaceutical and healthcare companies.
from July 2020 who May 2021, Mr. Souders served as President, Chief Executive Officer and Chairman of the Board of Directors of Vesper Healthcare Acquisition Corporation (“Vesper”) and led Vesper’s merger with HydraFacial Company to form The Beauty Health Company, of which he continues. Serve as Executive Chairman. Previously, he served as CEO and Chairman of Allergan plc (“Allergan”), known as the maker of Botox. July 2014 who May 2020and played a major role in the acquisition of Allergan by AbbVie, Inc. He also served on the board of Allergan. July 2014 who May 2020And since as its president October 2016 who May 2020.
Mr. Saunders previously served as Chief Executive Officer and President of Forest Laboratories, Inc. (“Forest”) and later as CEO of the pharmaceutical company Actavis, following that company’s acquisition of Forest. Later, Saunders negotiated the merger of Actavis with Allergan, which closed in June $70.5 billion. Mr. Saunders also held the role of Chief Executive Officer of Bausch + Lomb Inc., a leading global eye health company, where he oversaw the company’s 2013 acquisition by Valeant Pharmaceuticals. From 2003 to 2010, he held several leadership positions at Schering-Plough. Corporation, where he led the company’s merger with Merck & Company and the acquisition of Organon Biosciences. He is the founder of SPAC Vesper Healthcare Acquisitions, and currently BridgeBio Pharma, Inc. and also serves on the board of directors of Cisco (NASDAQ: CSCO ).
“Mr. Saunders’ experience in scaling and transforming biopharma and medical aesthetics businesses, first with Allergan and now with Beauty Health Company, makes him an invaluable asset to the GLO Pharma board,” says the chairman. Scott Glenn. “As we build our consumer brand Ourself’s product offering and roadmap of topical options for medical procedures, Brent brings incredible insight to the conversation, especially as we develop new innovations in the wrinkle relaxer category in the near future.”
This appointment follows the recent announcement of Rothie’s CFO Dayna Quanbeck on the GLO Pharma board, and the launch of GLO Pharma’s first consumer brand, Ourself, in February 2022. We have supported ourselves $40M Lightspeed Venture Partners, First Round Capital, and Mr. In funding so far from investors including Glenn.
Factory PR // Liz Hill
About GLO Pharma:
GLO Pharma is a biotechnology company dedicated to developing innovative approaches to beauty and aesthetics. It was established in 2018 Scott Glenn and Lauren Otsuki, innovators within the biotechnology space for over 20 years. Mr. Glenn and Ms. Otsuki founded and developed the professional skincare companies Elastin Skincare and SkinMedica in collaboration with several pharmaceutical companies with the goal of solving some of the most difficult medical problems of infertility, diabetes, heart disease, and cancer. In 2022, GLO Pharma launched its first consumer brand, Oursel, as the first Subtopical Skincare System™, bridging the gap between traditional skin care products and clinical procedures through the use of biotechnology.
View original content to download multimedia: https://www.prnewswire.com/news-releases/glo-pharma-appoints-current-executive-chairman-of-the-beauty-health-company-and-former-allergan-plc -ceo-brent-saunders-to-its-board-of-directors-301611368.html
Source GLO Pharma